Oncotelic Therapeutics (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement.
The integrated platform combines PDAOAI(TM) with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing. This creates potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMO). Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector.
This announcement is significant because it positions Oncotelic at the forefront of integrating artificial intelligence and robotics into pharmaceutical manufacturing, a sector increasingly focused on efficiency, quality control, and cost reduction. The platform’s ability to handle sterile manufacturing, electronic batch records, and cleanroom monitoring autonomously could reduce human error and contamination risks, potentially accelerating drug production timelines and lowering costs for biopharma companies.
For the pharmaceutical industry, the adoption of AI-driven GMP manufacturing could lead to faster scale-up of drug production, especially for sterile injectables, which are critical for many modern therapies. The platform also opens new revenue streams for Oncotelic through software licensing and automation services, diversifying its business model beyond drug development.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products. In addition to its drug pipeline, the company leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes. The company also holds a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates.
For more information, visit the company’s newsroom at https://nnw.fm/OTLC.
